Goldman Sachs’s Iterum Therapeutics ITRM Stock Holding History

Goldman Sachs’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,312	Closed	-$61K	–	6405
2022 Q2	$61K	Buy	+20,312	New	+$76K	﹤0.01%	5984
2020 Q2	–	Sell	-1,258	Closed	-$51K	–	5351
2020 Q1	$51K	Buy	+1,258	New	+$52.9K	﹤0.01%	5049
2018 Q3	–	Sell	-833	Closed	-$133K	–	5682
2018 Q2	$133K	Buy	+833	New	+$150K	﹤0.01%	5127

Other funds holding ITRM

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's ITRM Position: Q3 2022 in Review

Goldman Sachs sold out of Iterum Therapeutics (ITRM) in Q3 2022, closing a stake of 20,312 shares — an estimated $61K sold.

Goldman Sachs first reported a position in ITRM in Q2 2018 and held it in 3 quarters. The position peaked at $133K in Q2 2018. 25 funds tracked by Wall St. Rank hold ITRM as of Q3 2022.

Goldman Sachs reported no remaining Iterum Therapeutics position as of Q3 2022 after selling out during the quarter.
Goldman Sachs sold 20,312 Iterum Therapeutics shares in Q3 2022, an estimated $61K.
Goldman Sachs first reported a position in Iterum Therapeutics in Q2 2018 and held it in 3 quarters.
Goldman Sachs's Iterum Therapeutics position peaked at $133K in Q2 2018.
25 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.